Answers are grounded in this paper and cite their sources.
Prognostic benefit of AR was evident in patients with ADV score ≤4 log or absence of microvascular invasion. Patients with less aggressive tumor biology benefit more from AR than NAR, thus being reasonably indicated for AR.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: